Libia Susana Díez-Zuluaga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Libia Susana Díez-Zuluaga has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Jorge Sánchez
Group of Clinical and Experimental Allergy (GACE), Hospital “Alma Mater de Antioquia”, University of Antioquia, Medellín, Colombia
4 shared publications - Catalina Gómez-Henao
Clínica SOMER, Universidad de Antioquia
2 shared publications - Edison Morales
Allergology Unit Edificio Salud y Servicios Ciudad del Río Medellín Colombia
2 shared publications - Maria Angélica Muñoz-Ávila
Universidad de Antioquia, Grupo de Alergología Clínica y Experimental, Medellín
2 shared publications - Ricardo Cardona
Universidad de Antioquia, Grupo de Alergología Clínica y Experimental, Medellín
2 shared publications - Adriana Ocampo-Londoño1 shared publication
Latest Publications
- 17 November 2026
- Published by Springer Nature in Immunologic Research
- Vol. 74 (1)
National survey of the clinical profile and management of patients with hereditary angioedema due to C1-inhibitor deficiency in Colombia
- 17 November 2026
- Published by Springer Nature in Immunologic Research
- Vol. 74 (1)
National survey of the clinical profile and management of patients with hereditary angioedema due to C1-inhibitor deficiency in Colombia
- Open Access
- 12 May 2026
- Published by MDPI AG in Preprints.org
Diagnosis and Management of Hereditary Angioedema in Latin America: International Recommendations and Regional Practice Realities
Background: Current international hereditary angioedema (HAE) guidelines and treat-to-target recommendations consistently emphasize accurate diagnosis, early on-demand treatment of attacks, appropriate short-term prophylaxis for procedures, individualized long-term prophylaxis (LTP), and routine assessment of disease control and quality of life. Published information on how these recommendations are implemented in Latin America remains limited. We therefore aimed to assess the extent to which a Latin American expert panel converges with recommendations across current international HAE guidelines and consensus documents and to identify the principal barriers affecting real-world implementation in the region. Methods: A scientific committee developed and externally validated a 74-item questionnaire (domains summarized in Supplementary Table S1) and conducted a 2-round Delphi process among Latin American HAE experts. Consensus items were rated on a 9-point agreement scale, with consensus defined a priori as at least two-thirds of panelists scoring within a 3-point band in the agreement (7-9) or disagreement (1-3) range. Descriptive items captured expert-reported diagnostic testing, acute and preventive treatment patterns, monitoring practices, and implementation determinants using 5-point Likert scales. Instrument validation (July-November 2024) demonstrated high inter-rater agreement (Kendall W = 0.84; p < 0.001) and excellent internal consistency (Cronbach alpha = 0.92). Results: Thirty experts from 10 countries completed the process (Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Panama, Peru, Uruguay, Venezuela). Panel consensus broadly converged with recommendations across current international HAE guidelines and consensus documents on core diagnostic work-up (C4 plus C1-INH antigen and function; 84% consensus), selective use of genetics (97% consensus), first-line targeted LTP (pdC1-INH, Lanadelumab, Berotralstat; 94% consensus), retention of on-demand therapy for breakthrough attacks and for patients without access to LTP, routine monitoring, and management in special populations. The principal novel finding was an implementation feasibility gap: frequent or constant interruptions in prophylaxis supply were reported by 19/30 experts (63%), including 13/23 (57%) practicing in settings where public or insurance coverage was reported. Across the panel, cost (19/30; 63%) and medicine availability (8/30; 27%) were the most commonly cited barriers, with additional constraints related to diagnostic testing access and administrative pathways. Conclusions: Latin American expert consensus largely converges with recommendations across current international HAE guidelines and consensus documents on diagnosis, acute management, prophylaxis selection, monitoring, and special-population care. The dominant divergence is not clinical disagreement but implementation feasibility—particularly access to diagnostic testing, financing mechanisms, medicine availability, and continuity of supply. These findings provide region-specific evidence to contextualize international recommendations and support implementation strategies tailored to Latin America.
- 12 May 2026
- Published by MDPI AG in Preprints.org
Open AccessDiagnosis and Management of Hereditary Angioedema in Latin America: International Recommendations and Regional Practice Realities
Background: Current international hereditary angioedema (HAE) guidelines and treat-to-target recommendations consistently emphasize accurate diagnosis, early on-demand treatment of attacks, appropriate short-term prophylaxis for procedures, individualized long-term prophylaxis (LTP), and routine assessment of disease control and quality of life. Published information on how these recommendations are implemented in Latin America remains limited. We therefore aimed to assess the extent to which a Latin American expert panel converges with recommendations across current international HAE guidelines and consensus documents and to identify the principal barriers affecting real-world implementation in the region. Methods: A scientific committee developed and externally validated a 74-item questionnaire (domains summarized in Supplementary Table S1) and conducted a 2-round Delphi process among Latin American HAE experts. Consensus items were rated on a 9-point agreement scale, with consensus defined a priori as at least two-thirds of panelists scoring within a 3-point band in the agreement (7-9) or disagreement (1-3) range. Descriptive items captured expert-reported diagnostic testing, acute and preventive treatment patterns, monitoring practices, and implementation determinants using 5-point Likert scales. Instrument validation (July-November 2024) demonstrated high inter-rater agreement (Kendall W = 0.84; p < 0.001) and excellent internal consistency (Cronbach alpha = 0.92). Results: Thirty experts from 10 countries completed the process (Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Panama, Peru, Uruguay, Venezuela). Panel consensus broadly converged with recommendations across current international HAE guidelines and consensus documents on core diagnostic work-up (C4 plus C1-INH antigen and function; 84% consensus), selective use of genetics (97% consensus), first-line targeted LTP (pdC1-INH, Lanadelumab, Berotralstat; 94% consensus), retention of on-demand therapy for breakthrough attacks and for patients without access to LTP, routine monitoring, and management in special populations. The principal novel finding was an implementation feasibility gap: frequent or constant interruptions in prophylaxis supply were reported by 19/30 experts (63%), including 13/23 (57%) practicing in settings where public or insurance coverage was reported. Across the panel, cost (19/30; 63%) and medicine availability (8/30; 27%) were the most commonly cited barriers, with additional constraints related to diagnostic testing access and administrative pathways. Conclusions: Latin American expert consensus largely converges with recommendations across current international HAE guidelines and consensus documents on diagnosis, acute management, prophylaxis selection, monitoring, and special-population care. The dominant divergence is not clinical disagreement but implementation feasibility—particularly access to diagnostic testing, financing mechanisms, medicine availability, and continuity of supply. These findings provide region-specific evidence to contextualize international recommendations and support implementation strategies tailored to Latin America.
- 22 September 2025
- Published by Taylor & Francis in Immunotherapy
- Vol. 17 (14) , 995-1004
Diagnostic and therapeutic evaluation of Blomia tropicalis in patients with allergic rhinitis
To assess the clinical relevance of B. tropicalis IgE sensitization through nasal challenge test (NCT) and explore the effectiveness of immunotherapy (AIT) with this mite. A prospective cohort study was conducted in patients with moderate/severe persistent allergic rhinitis. In phase one, atopy tests for B. tropicalis were evaluated using NCT as reference parameter. In phase two, NCT-positive patients underwent AIT for 1 year, followed by a second NCT. Eighty patients sensitized to B. tropicalis were enrolled; 56% had a positive baseline NCT. The SPT and sIgE exhibited a sensitivity over 90%, but a specificity lower than 50% with an overall diagnostic accuracy of 64%. The sIgE to Blo t 5 exhibited a sensitivity of 59.9%, specificity of 80%, and overall diagnostic accuracy 72%. Of those with positive NCT, 39 started AIT. During the second NCT, 82% of these patients tolerated a B. tropicalis extract concentration tenfold higher than baseline. B. tropicalis is clinically relevant for allergic rhinitis patients, but atopy tests for this disease have a low specificity. AIT with B. tropicalis is a therapeutic tool for allergic rhinitis, mainly when a positive-NCT is demonstrated.
- 22 September 2025
- Published by Taylor & Francis in Immunotherapy
- Vol. 17 (14) , 995-1004
Diagnostic and therapeutic evaluation of Blomia tropicalis in patients with allergic rhinitis
To assess the clinical relevance of B. tropicalis IgE sensitization through nasal challenge test (NCT) and explore the effectiveness of immunotherapy (AIT) with this mite. A prospective cohort study was conducted in patients with moderate/severe persistent allergic rhinitis. In phase one, atopy tests for B. tropicalis were evaluated using NCT as reference parameter. In phase two, NCT-positive patients underwent AIT for 1 year, followed by a second NCT. Eighty patients sensitized to B. tropicalis were enrolled; 56% had a positive baseline NCT. The SPT and sIgE exhibited a sensitivity over 90%, but a specificity lower than 50% with an overall diagnostic accuracy of 64%. The sIgE to Blo t 5 exhibited a sensitivity of 59.9%, specificity of 80%, and overall diagnostic accuracy 72%. Of those with positive NCT, 39 started AIT. During the second NCT, 82% of these patients tolerated a B. tropicalis extract concentration tenfold higher than baseline. B. tropicalis is clinically relevant for allergic rhinitis patients, but atopy tests for this disease have a low specificity. AIT with B. tropicalis is a therapeutic tool for allergic rhinitis, mainly when a positive-NCT is demonstrated.
- 18 May 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (8) , 2208-2210
Parallel remission of nonsteroidal anti-inflammatory drugs-exacerbated cutaneous reactions and chronic spontaneous urticaria
- 18 May 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (8) , 2208-2210
Parallel remission of nonsteroidal anti-inflammatory drugs-exacerbated cutaneous reactions and chronic spontaneous urticaria
- Open Access
- 14 November 2019
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 66 (4) , 504-509
Síndrome de activación mastocitaria. A propósito de un caso clínico
Background: Monoclonal mast cell activation syndrome is included in mast cell activation disorders in which, after a diagnostic process, it is not possible to meet the required criteria for a diagnosis of systemic mastocytosis.Clinical case: A 73-year-old woman who presented two events of anaphylaxis 15 minutes after the intake of yucca; with a positive skin test, elevated tryptase, and mast cells with abnormal phenotype in the bone marrow biopsy, and without criteria for systemic mastocytosis.Conclusions: The diagnosis of monoclonal mast cell activation syndrome requires high clinical suspicion for patients with recurrent anaphylaxis and elevated tryptase, for whom joint management with hematology is essential.
- 14 November 2019
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 66 (4) , 504-509
Open AccessSíndrome de activación mastocitaria. A propósito de un caso clínico
Background: Monoclonal mast cell activation syndrome is included in mast cell activation disorders in which, after a diagnostic process, it is not possible to meet the required criteria for a diagnosis of systemic mastocytosis.Clinical case: A 73-year-old woman who presented two events of anaphylaxis 15 minutes after the intake of yucca; with a positive skin test, elevated tryptase, and mast cells with abnormal phenotype in the bone marrow biopsy, and without criteria for systemic mastocytosis.Conclusions: The diagnosis of monoclonal mast cell activation syndrome requires high clinical suspicion for patients with recurrent anaphylaxis and elevated tryptase, for whom joint management with hematology is essential.
- Open Access
- 14 June 2019
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 66 (2) , 205-216
Relación entre la sensibilización a camarón y ácaros. Exploración de la reactividad cruzada por tropomiosina
Background: Little is known about the sensitization to shrimp in patients with respiratory allergies who are sensitized to mites and about the clinical relevance of that sensitization in the tropical region. Objectives: To determine the prevalence of sensitization to shrimp in patients with rhinitis or asthma who are sensitized to mites, to explore the route of sensitization, its relevance, and the role of sensitization to tropomyosin. Methods: A cross-sectional study in patients with asthma and rhinitis who are sensitized to mites. Through a survey, it was asked about the consumption of shrimp and the control of asthma or rhinitis. Oral provocation tests were carried out with shrimp on individuals who are sensitized to mites and shrimp without consumption, or consumption greater than six months before, without reaction history. In a subgroup, the sIgE was measured for shrimp, Der p and Lit v 1. The patients who are sensitized to mites and shrimp (cases) were compared to the patients who are sensitized only to mites (controls).Results: Out of 229 patients, 48 (21%) were sensitized to shrimp. There wasn’t a statistically significant difference in the intake of shrimp between cases (54.2%) and controls (49.7%); eight cases showed symptoms on contact with shrimp. No statistically significant differences were found in the sIgE for Der p, Lit v1 and shrimp between cases and controls. A medium change was observed in the size of the effect: 0.45, 0.44 and 0.41 respectively.Conclusions: Sensitization to shrimp in patients with asthma or allergic rhinitis caused by mites is high; in 25% it seems to be clinically relevant, mainly in those with asthma. Intake is not the main route of exposure to tropomyosin; cross-reactivity can explain the frequency of sensitization.
- 14 June 2019
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 66 (2) , 205-216
Open AccessRelación entre la sensibilización a camarón y ácaros. Exploración de la reactividad cruzada por tropomiosina
Background: Little is known about the sensitization to shrimp in patients with respiratory allergies who are sensitized to mites and about the clinical relevance of that sensitization in the tropical region. Objectives: To determine the prevalence of sensitization to shrimp in patients with rhinitis or asthma who are sensitized to mites, to explore the route of sensitization, its relevance, and the role of sensitization to tropomyosin. Methods: A cross-sectional study in patients with asthma and rhinitis who are sensitized to mites. Through a survey, it was asked about the consumption of shrimp and the control of asthma or rhinitis. Oral provocation tests were carried out with shrimp on individuals who are sensitized to mites and shrimp without consumption, or consumption greater than six months before, without reaction history. In a subgroup, the sIgE was measured for shrimp, Der p and Lit v 1. The patients who are sensitized to mites and shrimp (cases) were compared to the patients who are sensitized only to mites (controls).Results: Out of 229 patients, 48 (21%) were sensitized to shrimp. There wasn’t a statistically significant difference in the intake of shrimp between cases (54.2%) and controls (49.7%); eight cases showed symptoms on contact with shrimp. No statistically significant differences were found in the sIgE for Der p, Lit v1 and shrimp between cases and controls. A medium change was observed in the size of the effect: 0.45, 0.44 and 0.41 respectively.Conclusions: Sensitization to shrimp in patients with asthma or allergic rhinitis caused by mites is high; in 25% it seems to be clinically relevant, mainly in those with asthma. Intake is not the main route of exposure to tropomyosin; cross-reactivity can explain the frequency of sensitization.
- Open Access
- 4 April 2019
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 66 (1) , 128-131
Asma de difícil control relacionada con tromboembolismo pulmonar y aspergilosis broncopulmonar
Background: Inflammation caused by chronic diseases and the constant use of systemic corticosteroids could be linked to the increased incidence of venous thromboembolic disease. Clinical case: A 47 year-old man with severe asthma of difficult control and allergic bronchopulmonary aspergillosis who, although the treatment was optimal, continued to have recurrent exacerbations and the need for systemic corticosteroids. He had edema in his left leg. Through venous Doppler ultrasound, deep vein thrombosis was confirmed; because of the images of the pulmonary V/Q gammagram, the presence of chronic pulmonary thromboembolism was suspected. 5 mg of apixaban were prescribed every 12 hours; in less than two months, symptom control was achieved without hospitalization, systemic corticosteroids or short-acting B2 agonists. Gradual withdrawal of omalizumab was started with good tolerance. Conclusions: The important decrease of bronchial symptoms with the blood thinner confirmed the suspicion that the exacerbations were caused by chronic pulmonary thromboembolism.
- 4 April 2019
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 66 (1) , 128-131
Open AccessAsma de difícil control relacionada con tromboembolismo pulmonar y aspergilosis broncopulmonar
Background: Inflammation caused by chronic diseases and the constant use of systemic corticosteroids could be linked to the increased incidence of venous thromboembolic disease. Clinical case: A 47 year-old man with severe asthma of difficult control and allergic bronchopulmonary aspergillosis who, although the treatment was optimal, continued to have recurrent exacerbations and the need for systemic corticosteroids. He had edema in his left leg. Through venous Doppler ultrasound, deep vein thrombosis was confirmed; because of the images of the pulmonary V/Q gammagram, the presence of chronic pulmonary thromboembolism was suspected. 5 mg of apixaban were prescribed every 12 hours; in less than two months, symptom control was achieved without hospitalization, systemic corticosteroids or short-acting B2 agonists. Gradual withdrawal of omalizumab was started with good tolerance. Conclusions: The important decrease of bronchial symptoms with the blood thinner confirmed the suspicion that the exacerbations were caused by chronic pulmonary thromboembolism.
- Open Access
- 4 July 2018
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 65 (2) , 148-159
Caracterización epidemiológica, clínica y diagnóstica de niños con gastroenteropatía eosinofílica. Estudio retrospectivo de tres instituciones de salud de alta complejidad
Background: Eosinophilic gastrointestinal disorders (EGID) are uncommon. In Colombia there are no studies in the pediatric population.Objective: To describe the epidemiological, clinical and diagnostic characteristics of a pediatric population with EGID.Methods: Observational, retrospective study in children aged between 0 and 12 years, assessed in three high complexity hospitals in Medellín, Colombia, between 2010 and 2015.Results: Out of 151 children, 74 (49%) had eosinophilic esophagitis, 35 (23.2%) had eosinophilic gastritis, 20 (13.2%), eosinophilic duodenitis, and 65 (43%) eosinophilic ileitis or colitis; 60.9% were males, and median age was 5 years; 66.9% had a history of allergic disease, and 78.8% had involvement of a single segment of the gastrointestinal tract. Main symptoms were abdominal pain and vomiting. Maximum eosinophil count per high power field (HPF) in the esophagus, stomach, duodenum, ileum and colon was 34, 21, 42, 45 and 60, respectively. Peripheral eosinophilia was more common in patients with esophageal and stomach involvement. The most sensitizing foods were egg, milk, shrimp, wheat and chicken. Proton pump inhibitors, steroids or immunosuppressants, as well as food-exclusion diets were used.Conclusions: EGID can compromise multiple segments, and its symptoms are unspecific; multidisciplinary management is required.
- 4 July 2018
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 65 (2) , 148-159
Open AccessCaracterización epidemiológica, clínica y diagnóstica de niños con gastroenteropatía eosinofílica. Estudio retrospectivo de tres instituciones de salud de alta complejidad
Background: Eosinophilic gastrointestinal disorders (EGID) are uncommon. In Colombia there are no studies in the pediatric population.Objective: To describe the epidemiological, clinical and diagnostic characteristics of a pediatric population with EGID.Methods: Observational, retrospective study in children aged between 0 and 12 years, assessed in three high complexity hospitals in Medellín, Colombia, between 2010 and 2015.Results: Out of 151 children, 74 (49%) had eosinophilic esophagitis, 35 (23.2%) had eosinophilic gastritis, 20 (13.2%), eosinophilic duodenitis, and 65 (43%) eosinophilic ileitis or colitis; 60.9% were males, and median age was 5 years; 66.9% had a history of allergic disease, and 78.8% had involvement of a single segment of the gastrointestinal tract. Main symptoms were abdominal pain and vomiting. Maximum eosinophil count per high power field (HPF) in the esophagus, stomach, duodenum, ileum and colon was 34, 21, 42, 45 and 60, respectively. Peripheral eosinophilia was more common in patients with esophageal and stomach involvement. The most sensitizing foods were egg, milk, shrimp, wheat and chicken. Proton pump inhibitors, steroids or immunosuppressants, as well as food-exclusion diets were used.Conclusions: EGID can compromise multiple segments, and its symptoms are unspecific; multidisciplinary management is required.